antibodies to leukocyte adhesion molecules have been demonstrated to ameliorate brain injury after ischemia! reperfusion Bowes et al., 1993; Chen et al., 1994; Matsuo et al., 1994) , Leukocyte adhesion to endothelial cells and to extra cellular matrix components has a complex molecular ba sis, and multiple adhesion receptor systems mediate the recruitment of leukocytes from the blood to the central nervous system (CNS) (Butcher, 1991) . The initial traf ficking of circulating leukocytes to sites of inflammation is mediated by the selectin family of adhesion receptors (Lasky, 1992; Bevilacqua and Nelson, 1993) , followed by engagement of additional cellular recognition recep tors, including the immunoglobulin superfamily and in tegrins (Hynes, 1987; Springer, 1990; Ruoslahti, 199 1) . Of the integrins, those containing [32 subunits are largely involved in cell-cell interactions, whereas [31 integrins usually are associated with mediating adhesion to extra cellular matrix constituents (Ruoslahti, 1991; Hynes, 1987; Springer, 1990) . One of these extracellular matrix macromolecules is fibronectin, which is found in plasma, cell matrix, and on the cell surface and can support leu kocyte adhesion to endothelial cells (Akiyama and Ya mada, 1987) . Fibronectin possesses multiple domains recognized by integrins, including arginyl-glycyl aspartic acid (ROD), which interacts with u S f3 1 [very late antigen (VLA)-5]; U3 f3 1 (VLA-3); and other integrins (Brown and Juliano, 1985; Elices et aI., 1991) , and the alternately spliced connecting segment (CS)-1 domain, which is recognized by u4 f3 1 (VLA-4) (Ouan and Hynes, 1990) . In addition to recognizing the CS-I domain of fibronectin, U4f3 1 also serves as a receptor for the vascu lar cell adhesion molecule (VCAM)-I. Along with the integrins, there is also increasing evidence for a role for cell surface proteoglycans in mediating early steps in the inflammatory process (lida et aI., 1992; Woods et aI., 1993) . In this regard, interest has focused on polypep tides derived from the 33-kDa carboxyl-terminal hepa rin-binding domain of fibronectin. Synthetic fibronectin peptides, synthesized at our institution from several fi bronectin domains for the specific purpose of inhibiting leukocyte adhesion, have shown promise in in vivo stud ies (Wahl et aI., 1994; Hines et aI., 1994) . We have previously demonstrated that a mixture of synthetic fi bronectin peptides reduces ischemic brain damage after transient focal cerebral ischemia in rats (Yanaka et aI., 1996) .
The purpose of the present study was to evaluate the efficacy of the individual peptides on leukocyte accumu lation, infarct size, and neurological outcome in a rat model of transient focal cerebral ischemia.
MATERIALS AND METHODS

General protocol
Forty-two male Sprague-Dawley rats, weighting 270-350 g each, were used in this study. The experiment was approved by the Animal Care Committee of the University of Minnesota and carried out under the auspices of Research Animal Resources, an American Association for the Accreditation of Laboratory Animal Care-approved facility.
Animals were allocated to one of five groups: transient ce rebral ischemia without treatment (Group I), treatment with i.v. administration of RGD peptide (Group II), treatment with i.v. administration of CS-l peptide (Group III), treatment with i. v. administration of FN-C/H-V peptide (Group IV), and treatment with Lv. administration of scrambled FN-C/H-V peptide (Group V). Seven animals were excluded from the study: six did not meet the selection criteria as described below and one died during the period of reperfusion due to unexpected hem orrhage at the operative site. Of the six that did not meet se lection criteria, one animal from Group I, one from Group III, and two from Group V were excluded from the study due to the presence of subarachnoid hemorrhage; one animal from Group I and one from Group II were also excluded because of the absence of neurological deficits. Each group was composed of seven animals.
Animal preparation and monitoring
All animal procedures were done under complete, general anesthesia. Anesthesia was induced with i.p. injection of a mix ture of ketamine (87 mg/kg) and xylazine (13 mg/kg). After induction, animals were ventilated through a face mask with a mixture of oxygen and air. Arterial Pc02 was maintained be-tween 35 and 40 torr. Rectal temperature was maintained be tween 37 and 38°C with heating pads. The right femoral artery was cannulated for monitoring arterial blood gas monitoring and peripheral white blood cell counting. Peripheral blood samples were obtained before induction of ischemia and at 48 h after reperfusion for measurem«nt of the number of pe ripheral white blood cells and differentials. Measurements were made using a Celldyne 3500 cell counter (Abbott Diagnostics, San Jose, CA, U.S.A.). A PE-IO catheter was introduced into the inferior vena cava via the right femoral vein for i.v. admin istration of synthetic fibronectin peptides.
Transient focal cerebral ischemia in the area perfused by middle cerebral artery (MCA) was induced. Briefly, an incision was made in the midline of the neck and the right carotid bifurcation was exposed. The internal carotid artery (ICA) was followed rostrally, and the pterygopalatine branch identified and ligated. The common carotid artery (CCA) was then oc cluded, and the branches of the external carotid artery (ECA) were dissected and divided. The occluder, a 4-0 nylon suture with a silicone-coated tip, was then advanced from the ECA into the lumen of the ICA until it blocked the origin of the MCA. The average size of the silicone-coated portion was 0.25 mm in diameter and 12.0 mm in length. We chose an occluder that blocked the MCA at a depth of 19-20 mm. This was chosen after preliminary work showed that this produced the most consistent infarction. Reperfusion was accomplished by withdrawal of the suture. Animals underwent ischemia for 1 h and reperfusion for 48 h. All animals included in the study became awake and lucid and exhibited a movement disturbance of the left forepaw within 60 min after reperfusion. After sur gery, animals were allowed free access to food and water. Neurological deficit characterized by left-sided hemiparesis and right Horner's syndrome were used as criteria for ischemic insult. Also excluded were any animals that had subarachnoid hemorrhage or lacked neurological deficits at 3 h after the induction of ischemia.
A neurological examination, as described by Zea Longa (1989) , was performed 12, 24, and 48 h after occlusion in a blinded fashion. A standard scoring scale was used: 0, normal; I, failure to extend the left forepaw; 2, circling to the left; 3, falling to the left; and 4, not walking spontaneously nor exhib iting a consciousness disturbance.
Fibronectin peptides synthesis and treatment
Fibronectin polypeptides containing the RGD domain, the alternatively spliced CS-I (Asp-Glu-Leu-Pro-Gln-Leu-Val Thr-Leu-Pro-His-Pro-Asn-Leu-His-Gly-Pro-Glu-Ile-Leu-Asp Val-Pro-Ser-Thr), and one nonoverlapping sequence corre sponding to the FN-C/H region (FN-CIH-V) (Trp-Gln-Pro-Pro Arg-Ala-Arg-Ile) were synthesized and purified as described (McCarthy et al., 1988 (McCarthy et al., , 1990 Wahl et aI., 1994; Woods et aI., 1993; Hines et aI., 1994) . Briefly, fibronectin peptides were synthesized at the Microchemical facility of the University of Minnesota using a Beckman system 990 peptide synthesizer (Beckman Instruments Inc., Fullerton, CA, U.S.A.). Lyophi lized crude peptides were purified by preparative reverse-phase high-pressure liquid chromatography (HPLC) on a C-18 col umn and were eluted with a linear gradient of acetonitrile (0-60%) containing 0.1 % trifluoroacetic acid in water. Peptide composition was verified by amino acid analysis before use. Peptide purity was >95% based on analytical HPLC. A scrambled version (SC-V) of the FN-CIH-V peptide, (Arg-Pro Gln-Ile-Pro-Trp-Ala-Arg-Tyr), was also synthesized. RGD peptide interacts with Ci 3 13!, cxsl3!, and 135 integrins (Hemler, 1990) , CS-l peptide interacts with Ci4131 integrin and VCAM, and FN-C/H-V has been reported to interact with proteoglycan and to inhibit adhesion to activated endothelial cells (Woods et aI., 1993; Wahl etal., 1994) .
Animals in Groups II, TIl, IV, and V received four i.v. ad ministrations of ISO f,LI of saline containing individual peptide (S mg/kg): 30 min prior to ischemia, at the time of reperfusion, and 3 and 24 h after reperfusion.
Measurement of infarct size
Four ischemic animals in each group were killed 48 h after reperfusion. Infarct size was measured as reported previously (Yanaka, et aI., 1996) . Briefly, brains were removed and kept at -80DC for S min. Each brain was then cut into 2-mm thick coronal blocks, for a total of seven blocks per brain. Brain slices were incubated at 37°C for 30 min in 2c/c 2,3,S-triphenyl-2H-tetrazolium chloride (TTC). The regions unstained by TTC, which refl ect mitochondrial damage, were quantified as the infarct areas. A tight correlation between histopathology and staining results within 3 days after the onset of ischemia in rat brain has been reported (Clark et a!., 1993) . The surface of each slice was digitized and the total and infarcted volumes were calculated blindly using three-dimensional reconstruction soft ware (Jandel PC3D, Corte Madera, CA, U.S.A.).
Myeloperoxidase activity assay
The activity of myeloperoxidase (MPO), an enzyme local ized in the azurophilic granules of leukocytes, is thought to be a quantitative index of polymorphonuclear leukocyte (PMN) presence (Barone et a!., 1991) . For the biochemical determina tion of MPO activity, three ischemic animals in each group were anesthetized and perfused transcardially with ISO ml of physiological saline (2S0C at a pressure of 100 mm Hg) at 48 h after reperfusion. Brain samples of the ischemic and contra lateral hemispheres were taken from the MCA area, immedi ately frozen in powdered dry ice, and stored at -80°C for later biochemical analysis. The method used to quantitate MPO ac tivity from rat brain samples was similar to that recently de scribed by Barone et a!. (1991) , but with minor modifications. The modified MPO assay for brain tissue was conducted blindly as follows: brain samples were thawed on ice, the cor tical tissues were dissected from the subcortical portion, and wet weight (in grams) of the cortical tissue measured. Each sample was homogenized (I :20, wt/vol) in S mmollL potassium phosphate buffer (pH 6.0, 4°C) using an Overhead-Stirrer (Wheaton Instruments, Millvill, NJ, U.S.A.) and centrifuged at 30,000 g (30 min, 4°C) (JS-H2 Centrifuge, Beckman Instru ments, Palo Alto, CA, U.S.A.). The supernatant was discarded and the pellet was washed again as described above. After decanting the supernatant, the pellet was extracted by suspen sion in O.S% hexadecyltrimethylammonium bromide (HTAB) (Sigma Chemical Co., St. Louis, MO, U.S.A.) in SO mmollL potassium phosphate buffer (pH 6.0, 4°C) for 2 min at an original tissue wet weight/volume ratio of I: I O. Samples were immediately frozen on powdered dry ice. Three freeze and thaw cycles were performed with sonications (lO s each, 2S0C), using a CU-6 ultrasonicator (Branson, Shelton, CT, U.S.A.) between cycles. After the last sonication, the samples were incubated at 4°C for 20 min and centrifuged at 12,SOO g (IS min, 4°C). Supernatant MPO activity was assayed as described earlier (Bradley et a!., 1982) . Briet1y, 0.1 ml of supernatant was mixed with 2.9 ml of SO mmollL potassium phosphate buffer, pH 6.0, containing 0.167 mg of O-dianisidine dihydrochloride (Sigma) and O.OOOS% hydrogen peroxide (Sigma). The change in absorbance at 460 nm was measured at IS-s intervals over 2 min, using a DU-64 spectrophotometer (Beckman). One unit of MPO activity is defined as that which degrades I f,Lmol of peroxide/min at 2S°C. MPO activity in the ischemic cortical tissue of Groups III and IV show a significant decrease when compared to that of Groups I, II, and V (p < 0.05) (*).
Statistics
All values are expressed as mean ± SD. A one-way analysis of variance (ANOV A) was performed on data of MPO activity, size of infarction, and peripheral leukocyte counts. A two-way ANOV A with Tukey multiple comparisons was carried out to compare neurological outcomes. Differences were considered significant if p < O.OS.
RESULTS
MPO activity
Mean MPO activity (U/g wet tissue) in the ischemic cortex was as follows (Fig. 1) : Group 1, 0.20 ± 0.05; Group II, 0.22 ± 0.05; Group III, 0.09 ± 0.01; Group IV, 0.10 ± 0.06; and Group V, 0.21 ± 0.04. Groups III and IV showed a significant decrease in MPO activity in the lesion when compared to Groups I, II, and V (p < 0.05). Mean MPO activity in the contralateral cortex was as follows: Group J, 0.03 ± 0.02; Group II, 0.04 ± 0.01; Group III, 0.05 ± 0.01; Group IV, 0.06 ± 0.03; and Group Y, 0.04 ± 0.02.
Infarct volume
Mean infarct size, expressed as a percentage of the total hemispheric volume ± SD, was as follows (Fig. 2) : Group I, 46.08 ± 4.74%; Group II, 50.31 ± 7.76%; Group III, 32.61 ± 4.96%; Group IV, 33.78 ± 5.63%; and Group Y, 45.03 ± 8.96%. Groups III and IV showed a signifi cant decrease in the size of infarction when compared to Groups I, II, and V (p < 0.05).
Neurological assessment
Neurological grades of the animals are summarized in Fig. 3 . The neurological grades of Groups III and IV were significantly better than those of Groups I, II, and V (p < 0.01) at 48 h after reperfusion (Fig. 3 ).
Peripheral leukocyte counting
No significant differences were detected in the number of leukocytes and differentials after peptide administra tion. Peptide treatment groups showed a tendency to wards decreases in the number of leukocytes after ad ministration of peptides, but these decreases were not statistically significant and were within normal physi ological range (Table I ).
DISCUSSION
The current study demonstrates that i.v. administration of certain bioactive adhesive fibronectin peptides signifi cantly inhibits the infiltration of leukocytes into ischemic tissue, reduces the size of infarction, and reduces neuro logical dysfunction after transient focal cerebral isch emia in rats. Treatment with C\'4 � I integrin-binding CS-I peptide or adhesion-promoting, heparin-binding syn thetic peptide, referred to as FN-C/H-V, resulted in at tenuation of the inflammatory response. However, the scrambled version of FN-C/H-V and C\' 5 � 1 integrin binding RGD peptide had no significant effect.
Leukocyte adhesion has been shown to occur via highly specific receptor/ligand-mediated interactions with endothelium and the extracellular matrix. PMNs constitutively express adhesion molecules on their plasma membranes and can rapidly alter their functional state in response to specific stimuli. Much emphasis has been placed on �2 integrin (Mac-I, LFA-1)-intercellular adhesion molecule (ICAM)-1 interactions in mediating leukocyte recruitment to sites of cerebral infarction, and on the potential value of blocking this interaction in the control of PMN and monocyte emigration Bowes et al., 1993; Chen et al., 1994) . The � I integrins exhibit considerable specificity in their ability to bind extracellular matrix molecules (Hemler, 1990) . Because of their low surface density, �l integrins were believed to be absent from PMNs, and the function of PMN �l integrin adherence-related events is largely un known (Hemler, 1990) .
At first glance, the reduction of PMN accumulation by C\'4 � I integrin-binding CS-I peptide seems inconsistent, as PMNs are devoid of cell surface C\'4 � 1 integrins. PMNs are detected as early as 30 min and reach a peak at 24 h after ischemia in rat brain (Garcia et al., 1994) . In con trast, monocytes are first detected in ischemic tissue 4-6 h after cerebral ischemia in rats (Garcia et al., 1994) . Recent investigations have revealed a �2 integrin independent and a � I integrin-dependent mechanism in PMN accumulation (Hakkert et al., 1991; Winn et al., 1993) . �2 integrin-independent PMN migration into in flammatory tissue after recruitment of monocytes has There were no significant differences between groups, and all values were within normal physiological range; xl,OOO/mm'; mean ± SO .
been observed (Mileski et a!., 1990) , and PMN migration has been thought to be initiated, in part, by a factor released by monocytes (Mileski et a!., 1990; Doerschuk et a!., 1990; Winn et a!., 1993) . Monocytes express 13 1 integrins, including VLA-4, on their surface (Hemler, 1990) . There is evidence that synthetic CS-l peptide can inhibit monocyte adhesion (Wahl et aI., 1994; . Therefore, synthetic CS-l peptides may pre vent PMN accumulation by blocking monocyte function.
Although the role of synthetic FN-C/H-V in mediating adhesion of leukocytes is incompletely understood, this peptide has been shown previously to inhibit adhesion of acitvated monocytes to cytokine-acti vated endothelial cells . This suggests that its ability to inhibit adhesion to endothelial cells is through a mecha nism similar to that of the CS-I peptide. Additionally, this peptide adheres to cell surface proteoglycans and modifies leukocyte adhesion (Woods et aI., 1993) . If pro teoglycans are involved in peptide FN-C/H-V action, then this peptide might antagonize selectins, since pro teoglycan interactions with selectins have been shown to facilitate leukocyte rolling (Norgard-Sumnichit et aI., 1993) . Moreover, proteoglycans have recently been im plicated in the function of 132 integrins (Diamond et aI., 1995) . Understanding the mechanism of FN-C/H-V ac tion could yield new information regarding the molecular basis of leukocyte/endothelial interactions.
The synthetic ROD peptide, which interacts with as l3 l integrin, did not reduce leukocyte accumulation in the ischemic tissue. Synthetic ROD peptide may become se questered or metabolized more rapidly than other pep tides, thus accounting for the negative results. However, in contrast to synthetic CS-l and FN -C/H -V peptides, the ROD peptide does not inhibit adhesion to endothelial cells (Osborne, 1990; Bevilacqua and Nelson, 1993) . VCAM-l, on the surface of cytokine-activated endothe lials cells, supports the adhesion of monocytes through an interaction with a4 13 1 integrin (Butcher, 1991; Os borne, 1990) . It is possible that the a4 13 1 integrin dependent pathway may be more important than the as l3 l integrin-dependent pathway in leukocyte accumulation in ischemic tissue.
Dose-response effect and optimal timing of adminis tration of synthetic fibronectin peptides for brain protec tion will be discussed in a subsequent article. We have not revealed the multiple interactions of leukocytes with other adhesion receptors whose blockade reduces infarct size. We hypothesized that monocytes would play an important role in PMN accumulation, but these hypoth eses have not yet been confirmed. Further experiments are required to resolve these issues, which are presently being addressed in our laboratory. However, the present studies clearly demonstrated the effectiveness of syn thetic fibronectin peptides in brain protection following ischemic insult. Thus, although the role of integrins and J Cereb Blood Flow Metah, Vol. 16, No.6, 1996 other cell adhesion molecules in mediating adhesion of cells is complex and incompletely understood. emerging evidence suggests that agents that inhibit or modulate the adhesion process may provide a mechanism by which to regulate inflammation and ischemiaJreperfusion injury. Understanding the functional properties of the protective peptides will offer insight into the mechanisms by which the active sequences provide an effective barrier to the pathological events associated with continued recruit ment and activation of leukocytes in infarcted/reperfused brain.
